- Home
- PLUS vs BEAM Comparison
PLUS vs BEAM Comparison
Compare PLUS & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLUS
- BEAM
- Stock Information
- Founded
- PLUS 1990
- BEAM 2017
- Country
- PLUS United States
- BEAM United States
- Employees
- PLUS N/A
- BEAM N/A
- Industry
- PLUS Retail: Computer Software & Peripheral Equipment
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PLUS Technology
- BEAM Health Care
- Exchange
- PLUS Nasdaq
- BEAM Nasdaq
- Market Cap
- PLUS 1.7B
- BEAM 1.6B
- IPO Year
- PLUS 1996
- BEAM 2020
- Fundamental
- Price
- PLUS $71.79
- BEAM $16.76
- Analyst Decision
- PLUS
- BEAM Strong Buy
- Analyst Count
- PLUS 0
- BEAM 11
- Target Price
- PLUS N/A
- BEAM $48.90
- AVG Volume (30 Days)
- PLUS 169.5K
- BEAM 1.8M
- Earning Date
- PLUS 08-05-2025
- BEAM 08-05-2025
- Dividend Yield
- PLUS N/A
- BEAM N/A
- EPS Growth
- PLUS N/A
- BEAM N/A
- EPS
- PLUS 4.05
- BEAM N/A
- Revenue
- PLUS $2,068,789,000.00
- BEAM $63,578,000.00
- Revenue This Year
- PLUS $3.88
- BEAM N/A
- Revenue Next Year
- PLUS $2.84
- BEAM $8.82
- P/E Ratio
- PLUS $17.59
- BEAM N/A
- Revenue Growth
- PLUS N/A
- BEAM N/A
- 52 Week Low
- PLUS $53.83
- BEAM $13.53
- 52 Week High
- PLUS $106.98
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- PLUS 60.71
- BEAM 44.29
- Support Level
- PLUS $68.00
- BEAM $16.18
- Resistance Level
- PLUS $73.36
- BEAM $18.33
- Average True Range (ATR)
- PLUS 1.54
- BEAM 1.10
- MACD
- PLUS -0.27
- BEAM 0.00
- Stochastic Oscillator
- PLUS 70.71
- BEAM 28.65
About PLUS ePlus inc.
ePlus Inc is a holding company. ePlus through its subsidiaries provides information technology solutions. The company's technology solutions enable organizations to optimize their IT environment and supply chain processes. It also provides consulting, professional and managed services, and complete lifecycle management services including flexible financing solutions. ePlus focuses on selling to medium and large enterprises in the United States and to customers in select international markets including the United Kingdom, the European Union, India, Singapore and Israel.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.